LifeArc
@lifearc.bsky.social
Medical research non-profit transforming promising life science ideas into medical breakthroughs that change patients’ lives.
The first patient has been treated in an early-phase clinical trial investigating whether a new medical device, Carbalive, can slow disease progression of a rare liver disease.
We are proud to fund this trial through our Pathfinder Programme.
🔗 https://t.ly/0BYtw
We are proud to fund this trial through our Pathfinder Programme.
🔗 https://t.ly/0BYtw
November 14, 2025 at 9:15 AM
The first patient has been treated in an early-phase clinical trial investigating whether a new medical device, Carbalive, can slow disease progression of a rare liver disease.
We are proud to fund this trial through our Pathfinder Programme.
🔗 https://t.ly/0BYtw
We are proud to fund this trial through our Pathfinder Programme.
🔗 https://t.ly/0BYtw
Patient voices have been involved at every stage of establishing a UK-wide network of research hubs improving how lung infections are managed. Read more about how we work with patients: https://www.lifearc.org/work-with-us/patients-community/
@cysticfibrosis.org.uk
@cysticfibrosis.org.uk
November 13, 2025 at 9:15 AM
Patient voices have been involved at every stage of establishing a UK-wide network of research hubs improving how lung infections are managed. Read more about how we work with patients: https://www.lifearc.org/work-with-us/patients-community/
@cysticfibrosis.org.uk
@cysticfibrosis.org.uk
Yesterday, over 100 people working on the Translational Centres for Rare Disease gathered to share achievements from their first year of operation and upcoming plans, as well as discuss important themes that affect the rare disease ecosystem in the UK.
November 12, 2025 at 2:36 PM
Yesterday, over 100 people working on the Translational Centres for Rare Disease gathered to share achievements from their first year of operation and upcoming plans, as well as discuss important themes that affect the rare disease ecosystem in the UK.
If you weren't able to attend #GAMRIC2025, or you want to catch up on sessions you missed, a comprehensive round-up is now live, covering each session of the conference in detail ➡️ https://www.gamric.org/about-gamric/conference-round-up/
@carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social
@carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social
Conference round-up
www.gamric.org
November 11, 2025 at 9:15 AM
If you weren't able to attend #GAMRIC2025, or you want to catch up on sessions you missed, a comprehensive round-up is now live, covering each session of the conference in detail ➡️ https://www.gamric.org/about-gamric/conference-round-up/
@carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social
@carb-x.bsky.social @escmid.bsky.social @gardp.bsky.social
Researchers, philanthropists, industry and other partners working in childhood cancer -- join our international consortium, C-Further, with your expertise, capabilities, ideas and investment.
November 7, 2025 at 9:15 AM
Researchers, philanthropists, industry and other partners working in childhood cancer -- join our international consortium, C-Further, with your expertise, capabilities, ideas and investment.
Just like yesterday's fireworks displays, this network of mature motor neurons is colourfully displaying their expression of MAP2 (red), ISL1 (orange), and SMI32 (green) with their blue nuclei.
This image is courtesy of our team working on our iPSC platform.
Photo: Will Stebbeds
This image is courtesy of our team working on our iPSC platform.
Photo: Will Stebbeds
November 6, 2025 at 9:15 AM
Just like yesterday's fireworks displays, this network of mature motor neurons is colourfully displaying their expression of MAP2 (red), ISL1 (orange), and SMI32 (green) with their blue nuclei.
This image is courtesy of our team working on our iPSC platform.
Photo: Will Stebbeds
This image is courtesy of our team working on our iPSC platform.
Photo: Will Stebbeds
What does patient engagement mean to us?
Working with patients, carers and communities to gather insights that shape research and improve health outcomes.
From setting priorities to guiding funding decisions, the patient voice is at the heart of our work.
🔗Learn more: https://t.ly/9e8yO
Working with patients, carers and communities to gather insights that shape research and improve health outcomes.
From setting priorities to guiding funding decisions, the patient voice is at the heart of our work.
🔗Learn more: https://t.ly/9e8yO
November 5, 2025 at 9:15 AM
What does patient engagement mean to us?
Working with patients, carers and communities to gather insights that shape research and improve health outcomes.
From setting priorities to guiding funding decisions, the patient voice is at the heart of our work.
🔗Learn more: https://t.ly/9e8yO
Working with patients, carers and communities to gather insights that shape research and improve health outcomes.
From setting priorities to guiding funding decisions, the patient voice is at the heart of our work.
🔗Learn more: https://t.ly/9e8yO
Rare disease research needs a more integrated and collaborative approach.
Next week, experts from across our 4 Translational Centres for Rare Disease, will meet to discuss the year's progress, share knowledge, and discuss the challenges and opportunities to come.
Next week, experts from across our 4 Translational Centres for Rare Disease, will meet to discuss the year's progress, share knowledge, and discuss the challenges and opportunities to come.
November 4, 2025 at 9:15 AM
Rare disease research needs a more integrated and collaborative approach.
Next week, experts from across our 4 Translational Centres for Rare Disease, will meet to discuss the year's progress, share knowledge, and discuss the challenges and opportunities to come.
Next week, experts from across our 4 Translational Centres for Rare Disease, will meet to discuss the year's progress, share knowledge, and discuss the challenges and opportunities to come.
We are pleased to see this new paper from the @mhragovuk.bsky.social, committing the UK to major reform in therapies for rare disease. The UK has the potential to be a hub for innovative rare disease research and care.
t.ly/usXH6
t.ly/usXH6
Major change for rare disease treatments on way, signals MHRA
New paper sets out UK regulator's intentions to overhaul rulebook for rare disease therapies in UK
t.ly
November 3, 2025 at 9:53 AM
We are pleased to see this new paper from the @mhragovuk.bsky.social, committing the UK to major reform in therapies for rare disease. The UK has the potential to be a hub for innovative rare disease research and care.
t.ly/usXH6
t.ly/usXH6
Happy Halloween from some spooky A549 cells and their E3 ligase expression (or haunting lack of in the nucleus).
Photo credit: Chloe Sanders
Photo credit: Chloe Sanders
October 31, 2025 at 11:54 AM
Happy Halloween from some spooky A549 cells and their E3 ligase expression (or haunting lack of in the nucleus).
Photo credit: Chloe Sanders
Photo credit: Chloe Sanders
TROP-2 is an attractive cancer target that is overexpressed on solid tumours. Yet, developing effective safe therapies targeting it remains a challenge.
With KisoJi, we've humanised the first unconjugated anti-TROP-2 antibody showing strong efficacy in vivo: https://t.ly/qRRSs
With KisoJi, we've humanised the first unconjugated anti-TROP-2 antibody showing strong efficacy in vivo: https://t.ly/qRRSs
October 30, 2025 at 9:00 AM
TROP-2 is an attractive cancer target that is overexpressed on solid tumours. Yet, developing effective safe therapies targeting it remains a challenge.
With KisoJi, we've humanised the first unconjugated anti-TROP-2 antibody showing strong efficacy in vivo: https://t.ly/qRRSs
With KisoJi, we've humanised the first unconjugated anti-TROP-2 antibody showing strong efficacy in vivo: https://t.ly/qRRSs
Science + precision + creativity: 3 of our chemical biologists recently learned to use a cutting-edge liquid-handling robot for high-throughput experimentation, and tested their skills by programming it to dispense coloured solutions into a 384-well plate to recreate our logo 🧪
October 29, 2025 at 9:00 AM
Science + precision + creativity: 3 of our chemical biologists recently learned to use a cutting-edge liquid-handling robot for high-throughput experimentation, and tested their skills by programming it to dispense coloured solutions into a 384-well plate to recreate our logo 🧪
Epidermolysis bullosa (EB) is a rare genetic condition causing extremely fragile skin that blisters and tears easily.
With no cures currently available, we've teamed up with @charitydebra.bsky.social to fund a drug-repurposing clinical trial to help change that.
🔗 Learn more: t.ly/vUByj
With no cures currently available, we've teamed up with @charitydebra.bsky.social to fund a drug-repurposing clinical trial to help change that.
🔗 Learn more: t.ly/vUByj
DEBRA UK and @lifearc.bsky.social have provisionally agreed to fund ART-EB - a multi-million-pound, 5-year drug repurposing trial, and the largest single investment in global EB research to date. 🧬
Learn more about the project & what it means for the EB community: https://bit.ly/42VRRD8
Learn more about the project & what it means for the EB community: https://bit.ly/42VRRD8
LifeArc and DEBRA UK to partner in multi-million drug repurposing trial
This project, known as the ART (Advancing Repurposed Therapeutics) EB trial, will be the single largest investment yet in global EB research.
www.debra.org.uk
October 27, 2025 at 2:43 PM
Epidermolysis bullosa (EB) is a rare genetic condition causing extremely fragile skin that blisters and tears easily.
With no cures currently available, we've teamed up with @charitydebra.bsky.social to fund a drug-repurposing clinical trial to help change that.
🔗 Learn more: t.ly/vUByj
With no cures currently available, we've teamed up with @charitydebra.bsky.social to fund a drug-repurposing clinical trial to help change that.
🔗 Learn more: t.ly/vUByj
In 2024, we held 4 workshops with our MND Insights Group, conducted 2 community surveys and published the MND Insights Report, sharing the findings with researchers and decision-makers.
You can find out more about this group and the report here: https://www.lifearc.org/project/mnd-insights-group/
You can find out more about this group and the report here: https://www.lifearc.org/project/mnd-insights-group/
October 25, 2025 at 8:00 AM
In 2024, we held 4 workshops with our MND Insights Group, conducted 2 community surveys and published the MND Insights Report, sharing the findings with researchers and decision-makers.
You can find out more about this group and the report here: https://www.lifearc.org/project/mnd-insights-group/
You can find out more about this group and the report here: https://www.lifearc.org/project/mnd-insights-group/
Monoclonal antibodies save lives — but high manufacturing costs keep them out of reach in low-resource settings. With the Gates Foundation, we've awarded over $5 million to 7 projects aimed at cutting manufacturing costs and making mAbs more affordable.
Read about the projects: https://t.ly/mrjH-
Read about the projects: https://t.ly/mrjH-
October 23, 2025 at 2:00 PM
Monoclonal antibodies save lives — but high manufacturing costs keep them out of reach in low-resource settings. With the Gates Foundation, we've awarded over $5 million to 7 projects aimed at cutting manufacturing costs and making mAbs more affordable.
Read about the projects: https://t.ly/mrjH-
Read about the projects: https://t.ly/mrjH-
Through our Childhood Cancer Translational Challenge, we're committed to helping deliver better treatments, better decisions and better trials for children with cancer.
Hear from David Jenkinson on how we've begun delivering on that promise: https://t.ly/aycRf
Hear from David Jenkinson on how we've begun delivering on that promise: https://t.ly/aycRf
One year of our Childhood Cancer Translational Challenge
Enjoy the videos and music you love, upload original content, and share it all with friends, family, and the world on YouTube.
t.ly
October 22, 2025 at 8:13 AM
Through our Childhood Cancer Translational Challenge, we're committed to helping deliver better treatments, better decisions and better trials for children with cancer.
Hear from David Jenkinson on how we've begun delivering on that promise: https://t.ly/aycRf
Hear from David Jenkinson on how we've begun delivering on that promise: https://t.ly/aycRf
@marcaurelbusche.bsky.social is exploring exactly that in one of the 5 projects we’re funding as part of the @ukdri.ac.uk Translation Awards: https://t.ly/C3vOl
October 21, 2025 at 8:15 AM
@marcaurelbusche.bsky.social is exploring exactly that in one of the 5 projects we’re funding as part of the @ukdri.ac.uk Translation Awards: https://t.ly/C3vOl
With Professor Joanna Zakrzewska at @ucl.ac.uk, we analysed GP records to uncover patterns in trigeminal neuralgia diagnosis –building the evidence needed to establish centres of excellence for faster, earlier care.
October 20, 2025 at 10:27 AM
With Professor Joanna Zakrzewska at @ucl.ac.uk, we analysed GP records to uncover patterns in trigeminal neuralgia diagnosis –building the evidence needed to establish centres of excellence for faster, earlier care.
ICYMI: A new round of funding for antimicrobial resistance innovators has opened through PACE. The round closes 5 November, supporting new therapeutics for serious bacterial infections that pose the greatest risk to human health.
Link to apply in the comments!
onenucleus.com/pace-announc...
Link to apply in the comments!
onenucleus.com/pace-announc...
PACE Announces £6 Million Funding for Antibacterial Treatment Innovations to Fill Critical Gap in R&D Pipeline | One Nucleus
PACE (Pathways to Antimicrobial Clinical Efficacy) launches its third funding round today, supporting innovative projects that tackle resistant bacterial infections posing the greatest threat to globa...
onenucleus.com
October 18, 2025 at 8:22 AM
ICYMI: A new round of funding for antimicrobial resistance innovators has opened through PACE. The round closes 5 November, supporting new therapeutics for serious bacterial infections that pose the greatest risk to human health.
Link to apply in the comments!
onenucleus.com/pace-announc...
Link to apply in the comments!
onenucleus.com/pace-announc...
🎓 This year, we have industrial placement students joining our teams across data science, molecular and cellular pharmacology, analytics, and more! We're proud to support the next generation of scientists, helping them develop their skills and make an impact early in their careers.
October 16, 2025 at 8:15 AM
🎓 This year, we have industrial placement students joining our teams across data science, molecular and cellular pharmacology, analytics, and more! We're proud to support the next generation of scientists, helping them develop their skills and make an impact early in their careers.
Since 2019, we have collaborated with Cleveland Clinic on impactful research initiatives. Together, we have now identified new research areas of mutual interest, including antibody discovery initiatives, and continuous education for clinician scientists.
October 14, 2025 at 4:00 PM
Since 2019, we have collaborated with Cleveland Clinic on impactful research initiatives. Together, we have now identified new research areas of mutual interest, including antibody discovery initiatives, and continuous education for clinician scientists.
In our recent blog, our Head of Childhood Cancer, David Jenkinson, reflects on the transformative potential CAR T-cell therapies could have for children with cancer: https://t.ly/atV7A
October 13, 2025 at 8:00 AM
In our recent blog, our Head of Childhood Cancer, David Jenkinson, reflects on the transformative potential CAR T-cell therapies could have for children with cancer: https://t.ly/atV7A
Want to learn more about the translational development and manufacture of new gene therapies?
Innovation Hubs for Gene Therapies are now offering 3 new online training courses, created by NHS Blood and Transplant, @sheffielduni.bsky.social and @ucl.ac.uk
Learn more: https://t.ly/f-cc0
Innovation Hubs for Gene Therapies are now offering 3 new online training courses, created by NHS Blood and Transplant, @sheffielduni.bsky.social and @ucl.ac.uk
Learn more: https://t.ly/f-cc0
October 11, 2025 at 8:00 AM
Want to learn more about the translational development and manufacture of new gene therapies?
Innovation Hubs for Gene Therapies are now offering 3 new online training courses, created by NHS Blood and Transplant, @sheffielduni.bsky.social and @ucl.ac.uk
Learn more: https://t.ly/f-cc0
Innovation Hubs for Gene Therapies are now offering 3 new online training courses, created by NHS Blood and Transplant, @sheffielduni.bsky.social and @ucl.ac.uk
Learn more: https://t.ly/f-cc0
We're supporting 5 projects as part of the @ukdri.ac.uk Translation Award Programme – providing researchers with the funds to help transform early-stage discovery into tests, therapies and treatments that can have a real clinical impact in neurodegenerative disease.
October 10, 2025 at 8:30 AM
We're supporting 5 projects as part of the @ukdri.ac.uk Translation Award Programme – providing researchers with the funds to help transform early-stage discovery into tests, therapies and treatments that can have a real clinical impact in neurodegenerative disease.
What drives you to do your best at work?
Hear from our team about what keeps them motivated and makes them proud to be part of LifeArc.
If you're interested in being part of our team, see our careers page: https://www.lifearc.org/careers/
Hear from our team about what keeps them motivated and makes them proud to be part of LifeArc.
If you're interested in being part of our team, see our careers page: https://www.lifearc.org/careers/
October 8, 2025 at 8:30 AM
What drives you to do your best at work?
Hear from our team about what keeps them motivated and makes them proud to be part of LifeArc.
If you're interested in being part of our team, see our careers page: https://www.lifearc.org/careers/
Hear from our team about what keeps them motivated and makes them proud to be part of LifeArc.
If you're interested in being part of our team, see our careers page: https://www.lifearc.org/careers/